Literature DB >> 14656722

Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines.

Hui Shen1, Alex B Lentsch.   

Abstract

The CXC chemokine family includes members that possess angiogenic and angiostatic properties. Angiogenic CXC chemokines are produced by prostate cancer cells and contribute to prostate tumor growth. Production of angiostatic CXC chemokines by prostatic cells has not been previously studied. Here we show that normal prostate epithelial (PZ-HPV-7) cells produce low amounts of angiogenic CXC chemokines, whereas prostate cancer cells from primary (CA-HPV-10) and metastatic (PC-3) tumors produce progressively greater amounts. These effects were caused by progressive increases in activation of the transcription factor nuclear factor-kappa B in prostate cancer cells. Conversely, PZ-HPV-7 cells produced relatively high levels of angiostatic CXC chemokines, whereas CA-HPV-10 and PC-3 cells produced stepwise lower amounts. These effects were dependent on reduced activation of signal transduction and activator of transcription 1 (STAT1) in prostate cancer cells. These data suggest that there is progressive dysregulation of nuclear factor-kappa B and STAT1 in prostate cancer cells that leads to proangiogenic production of CXC chemokines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656722     DOI: 10.1152/ajpcell.00335.2003

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  12 in total

1.  Acetylation of Stat1 modulates NF-kappaB activity.

Authors:  Oliver H Krämer; Daniela Baus; Shirley K Knauer; Stefan Stein; Elke Jäger; Roland H Stauber; Manuel Grez; Edith Pfitzner; Thorsten Heinzel
Journal:  Genes Dev       Date:  2006-02-15       Impact factor: 11.361

2.  Surviving lethal septic shock without fluid resuscitation in a rodent model.

Authors:  Yongqing Li; Baoling Liu; Eugene Y Fukudome; Ashley R Kochanek; Robert A Finkelstein; Wei Chong; Guang Jin; Jennifer Lu; Marc A deMoya; George C Velmahos; Hasan B Alam
Journal:  Surgery       Date:  2010-06-19       Impact factor: 3.982

3.  Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-gamma in HaCaT cells, a human keratinocyte cell line.

Authors:  Xu-Feng Qi; Dong-Heui Kim; Yang-Suk Yoon; Jian-Hong Li; Dan Jin; Yung-Chien Teng; Soo-Ki Kim; Kyu-Jae Lee
Journal:  Br J Pharmacol       Date:  2009-07-07       Impact factor: 8.739

4.  The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.

Authors:  M N Thobe; J K Gray; D Gurusamy; A M Paluch; P K Wagh; P Pathrose; A B Lentsch; S E Waltz
Journal:  Oncogene       Date:  2011-05-30       Impact factor: 9.867

5.  Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth.

Authors:  Yi-Ping Zhu; Fang-Ning Wan; Yi-Jun Shen; Hong-Kai Wang; Gui-Ming Zhang; Ding-Wei Ye
Journal:  Oncotarget       Date:  2015-06-10

6.  Suppression of interferon lambda signaling by SOCS-1 results in their excessive production during influenza virus infection.

Authors:  Haitao Wei; Song Wang; Qinghuang Chen; Yuhai Chen; Xiaojuan Chi; Lianfeng Zhang; Shile Huang; George F Gao; Ji-Long Chen
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

7.  Systems biology: a therapeutic target for tumor therapy.

Authors:  Albrecht Reichle; Thomas Vogt
Journal:  Cancer Microenviron       Date:  2008-07-23

8.  The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.

Authors:  M N Thobe; D Gurusamy; P Pathrose; S E Waltz
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

9.  Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.

Authors:  Sakshi Sikka; Luxi Chen; Gautam Sethi; Alan Prem Kumar
Journal:  PPAR Res       Date:  2012-11-14       Impact factor: 4.964

10.  Inflammatory genetic markers of prostate cancer risk.

Authors:  Elizabeth A Tindall; Vanessa M Hayes; Desiree C Petersen
Journal:  Cancers (Basel)       Date:  2010-06-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.